TrialLancet (London, England)2015

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.

Feng-Cai Zhu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.